Want to see IN:SUPRIYA full AI Analyst Report?
Top Page
Supriya Lifescience Limited
(SUPRIYA)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹966.00
▲(28.63% Upside)
Action:Downgraded
Date:10/08/26
The score is primarily supported by strong financial performance, especially the conservative balance sheet and solid recent operating results. This is tempered by a mixed near-term technical picture and a relatively high P/E alongside a minimal dividend yield.
Positive Factors
Strong revenue growth
Strong multi-year revenue expansion indicates recovering demand and improving commercial traction across the API portfolio. Continued top-line growth can support better capacity utilization, broaden the company’s customer base, and provide a durable platform for operating profit growth over the next several quarters.
Negative Factors
Margin and earnings volatility
Profitability has not followed a consistently expanding path, as margins and earnings have fluctuated from earlier highs. Such variability can make future earnings less predictable and may reflect sensitivity to API mix, pricing conditions, or input costs, limiting the durability of reported profit growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Strong multi-year revenue expansion indicates recovering demand and improving commercial traction across the API portfolio. Continued top-line growth can support better capacity utilization, broaden the company’s customer base, and provide a durable platform for operating profit growth over the next several quarters.
Read all positive factors
Supriya Lifescience Limited (SUPRIYA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹73.65B
Dividend Yield0.11%
Average Volume (3M)19.46K
Price to Earnings (P/E)36.1
Beta (1Y)1.37
Revenue Growth28.14%
EPS Growth11.38%
CountryIN
Employees607
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)24.65
Shares Outstanding80,482,800
10 Day Avg. Volume22,737
30 Day Avg. Volume19,465
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)3.78
Price to Sales (P/S)5.46
P/FCF Ratio105.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)29.9
Revenue Forecast (FY)₹9.94B
Supriya Lifescience Limited Business Overview & Revenue Model
Company Description
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic,...
How the Company Makes Money
Supriya Lifescience primarily makes money by manufacturing and selling active pharmaceutical ingredients (APIs) to customers that formulate and market finished pharmaceutical products. Revenue is earned from (1) API sales across its product portfo...
Supriya Lifescience Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.75B | 8.28B | 6.96B | 5.57B | 4.51B | 5.19B |
| Gross Profit | 5.63B | 4.49B | 3.84B | 2.80B | 2.20B | 2.89B |
| EBITDA | 2.99B | 3.05B | 2.71B | 1.84B | 1.37B | 2.22B |
| Net Income | 1.98B | 2.09B | 1.88B | 1.19B | 898.57M | 1.52B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 13.57B | 11.12B | 9.21B | 8.20B | 7.35B |
| Cash, Cash Equivalents and Short-Term Investments | 788.67M | 788.67M | 791.54M | 749.56M | 1.58B | 2.25B |
| Total Debt | 0.00 | 54.35M | 53.80M | 54.88M | 224.68M | 274.15M |
| Total Liabilities | -11.98B | 1.59B | 1.16B | 1.06B | 1.21B | 1.19B |
| Stockholders Equity | 11.98B | 11.98B | 9.97B | 8.15B | 6.99B | 6.16B |
Cash Flow | ||||||
| Free Cash Flow | 133.16M | 429.88M | 101.89M | -323.48M | -422.13M | -111.03M |
| Operating Cash Flow | 555.65M | 1.95B | 1.73B | 1.13B | 661.87M | 488.01M |
| Investing Cash Flow | -304.29M | -1.88B | -1.52B | -1.74B | -1.24B | -598.22M |
| Financing Cash Flow | -10.75M | -79.93M | -82.33M | -223.59M | -102.76M | 1.50B |
Supriya Lifescience Limited Technical Analysis
Positive
751.00
Price Trends
873.88
Positive
878.35
Positive
775.46
Positive
Market Momentum
16.06
Positive
46.31
Neutral
14.08
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUPRIYA, the sentiment is Positive. The current price of 751 is below the 20-day moving average (MA) of 930.35, below the 50-day MA of 873.88, and below the 200-day MA of 775.46, indicating a neutral trend. The MACD of 16.06 indicates Positive momentum. The RSI at 46.31 is Neutral, neither overbought nor oversold. The STOCH value of 14.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SUPRIYA.
Supriya Lifescience Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹101.92B | 40.26 | ― | 0.22% | -27.51% | -34.49% | |
67 Neutral | ₹73.65B | 36.15 | ― | 0.11% | 28.14% | 11.38% | |
56 Neutral | ₹24.04B | 35.04 | ― | 0.11% | -20.86% | -34.51% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | ₹38.78B | -42.81 | ― | 0.07% | 78.89% | -50.10% | |
48 Neutral | ₹176.19B | -360.52 | ― | ― | 27.15% | 40.46% | |
47 Neutral | ₹22.28B | -308.28 | ― | 0.56% | 10.26% | -162.02% |
* General Sector Average
IN:SUPRIYA
Supriya Lifescience Limited
890.20
179.70
25.29%
IN:BLUEJET
Blue Jet Healthcare Limited
540.85
-120.62
-18.23%
IN:DCAL
Dishman Carbogen Amcis Ltd.
152.55
-133.30
-46.63%
IN:PANACEABIO
Panacea Biotec Limited
358.10
-73.15
-16.96%
IN:ZOTA
Zota Health Care Ltd.
1,342.10
-140.60
-9.48%
IN:ONESOURCE
OneSource Specialty Pharma Limited
1,524.00
-338.30
-18.17%
Supriya Lifescience Limited Corporate Events
Supriya Lifescience Schedules Virtual Investor Meet, Posts Presentation Online
Sep 20, 2026
Supriya Lifescience Limited has announced that its officials will hold a virtual group meeting with analysts and institutional investors on Friday, September 25, 2026, from 11:00 a.m. to 12:00 noon. The company has also made its latest investor pr...
Supriya Lifescience Seeks Shareholder Nod to Reappoint Whole Time Director via E-Voting
Jul 21, 2026
Supriya Lifescience Limited has initiated a postal ballot process to seek shareholder approval for the special resolution to re-appoint Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel for a three-year term from May 26, 202...
Supriya Lifescience Confirms SEBI Compliance on Dematerialised Securities
Jul 9, 2026
Supriya Lifescience Limited has reported that its registrar and share transfer agent, MUFG Intime India Private Limited, has issued a certificate confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.